Denosumab linked to lower fracture risk
24 August 2009
| by Amy Corderoy
Denosumab given subcutaneously twice yearly for 36 months is associated with a reduction in the risk of vertebral, nonvertebral, and hip fractures in women with osteoporosis, a study finds....
Want to read complete article? Please Sign in or Register.